Search

Your search keyword '"Daniel M. Geynisman"' showing total 4 results
Start Over Author "Daniel M. Geynisman" Publisher elsevier
4 results on '"Daniel M. Geynisman"'

1. Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy

Author

David Strauss, Briana Kaplunov, Alexander Kutikov, Daniel M. Geynisman, Kwan Lau, and Marc Smaldone

Subjects
Urothelial carcinoma, Renal transplant, Immunosuppression, Transplant patient, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Multimodal immunosuppression is the backbone of modern solid organ transplantation. However, immunosuppression itself is an independent risk factor for post-transplant malignancy. Although skin malignancy is the most common post-transplant malignancy, genitourinary cancers are also described. Dose reduction or cessation of immunosuppression has a beneficial role in the management of transplant patients with concomitant malignancy, but only limited data exist with respect to bladder cancer (BCa).We describe a patient who developed metastatic muscle invasive bladder cancer (MIBC) after diseased donor kidney transplant (DDKT) who was successfully managed with dose reduction and elimination of an immunosuppression regimen.

Published
2023
Full Text
View/download PDF

2. Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma

Author

Naveed Ali, Alexander Kutikov, and Daniel M. Geynisman

Subjects
Renal cell carcinoma, Paraneoplastic syndrome, Tyrosine kinase inhibitor therapy, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Paraneoplastic syndromes are commonly encountered in renal cell carcinoma, but neurological manifestations are rare. Herein we report a case of a patient with locally advanced renal cell carcinoma who presented with Parkinson-like symptoms which prohibited surgery due to poor performance status. However, a significant improvement was noted after tyrosine kinase inhibitor therapy, allowing the patient to proceed to curative surgery.

Published
2017
Full Text
View/download PDF

3. Neoadjuvant chemotherapy for penile cancer enabling organ preservation: A case of individualized management for bilateral lymph node metastasis and a bulky primary tumor

Author

Andrew McIntosh, Aeen M. Asghar, David Y.T. Chen, Alexander Kutikov, and Daniel M. Geynisman

Subjects
Cisplatin, Oncology, medicine.medical_specialty, Chemotherapy, Ifosfamide, Penectomy, business.industry, Urology, medicine.medical_treatment, 030232 urology & nephrology, Multimodal therapy, medicine.disease, Primary tumor, 03 medical and health sciences, Regimen, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Penile cancer, business, medicine.drug
Abstract

Penile cancer, most commonly squamous cell carcinoma (SCC), is rare in the United States and Europe but has an aggressive natural history. Due to disease rarity, randomized clinical trials demonstrating efficacious multimodal therapies for advanced disease are lacking. Multi-agent cisplatin-based neoadjuvant chemotherapy (NAC) utilizing the “TIP” regimen (paclitaxel, ifosfamide, and cisplatin) has demonstrated good clinical response rates in TxN2-3 disease.1 Clinical responders to NAC who undergo consolidative surgery show improved overall survival and time to progression. We present a case of invasive SCC of the penis with a bulky primary tumor and bilateral lymphadenopathy in a patient who refused initial penectomy. We discuss the role of NAC in this setting and our results employing multimodal therapy to facilitate a limited local excision.

Published
2018

4. Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma

Author

Alexander Kutikov, Daniel M. Geynisman, and Naveed Ali

Subjects
medicine.medical_specialty, Pathology, medicine.drug_class, Tyrosine kinase inhibitor therapy, Urology, medicine.medical_treatment, 030232 urology & nephrology, Locally advanced, lcsh:RC870-923, Gastroenterology, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, medicine, Neurological syndrome, Poor performance status, Tyrosine, business.industry, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, Nephrectomy, Clear cell renal cell carcinoma, Oncology, Paraneoplastic syndrome, business, 030217 neurology & neurosurgery
Abstract

Paraneoplastic syndromes are commonly encountered in renal cell carcinoma, but neurological manifestations are rare. Herein we report a case of a patient with locally advanced renal cell carcinoma who presented with Parkinson-like symptoms which prohibited surgery due to poor performance status. However, a significant improvement was noted after tyrosine kinase inhibitor therapy, allowing the patient to proceed to curative surgery.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results